BIOMERICA INC
BMRAdata completeness 75%16 fiscal years on fileData notes: no data for concept 'totalDebt'; no data for concept 'investmentsAtFairValue'; no data for concept 'netInvestmentIncome'; no data for concept 'gainsOnRealEstateSales'; no data for concept 'realEstateImpairment'; no data for concept 'dividendsPaid'
BIOMERICA INC earns about -215% on invested capital, and has bought back 77% of its shares over 5 years. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|
| Revenue | $18.9M1 | $5.34M2 | $5.42M3 | $5.31M4 | $4.45M4 |
| Net income | −$4.53M5 | −$7.14M6 | −$5.98M7 | −$4.97M8 | −$3.78M8 |
| Operating cash flow | −$479,0009 | −$5.47M10 | −$5.36M11 | −$3.84M12 | −$3.42M12 |
| Capital expenditure | $57,00013 | $64,00014 | $51,00015 | — | — |
| Free cash flow (derived) | −$536,0009 | −$5.54M10 | −$5.41M11 | — | — |
| Total debt | — | — | — | — | — |
| Cash & equivalents | $5.92M16 | $9.72M17 | $4.17M18 | $2.4M19 | $1.31M19 |
| Diluted shares | 12.7M | 14.2M | 2.1M | 2.3M | 2.9M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on $9.02 of net worth that earned you −$12.95 last year.
It earned an average -215% on invested capital over 5 years. Compare that to what it costs to fund the business.
seeing a moat in the numbers →Share count is down 77% over 5 years — management has been buying back stock, quietly handing owners a bigger slice.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 10-K · period ending 2022-05-31 · accession 0001493152-23-030254 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2023-05-31 · accession 0001493152-24-034208 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2024-05-31 · accession 0001641172-25-026041 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2025-05-31 · accession 0001493152-26-040851 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2022-05-31 · accession 0001493152-23-030254 (NetIncomeLoss)
- 10-K · period ending 2023-05-31 · accession 0001493152-24-034208 (NetIncomeLoss)
- 10-K · period ending 2024-05-31 · accession 0001641172-25-026041 (NetIncomeLoss)
- 10-K · period ending 2025-05-31 · accession 0001493152-26-040851 (NetIncomeLoss)
- 10-K · period ending 2022-05-31 · accession 0001493152-23-030254 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-05-31 · accession 0001493152-24-034208 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2024-05-31 · accession 0001641172-25-026041 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2025-05-31 · accession 0001493152-26-040851 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-05-31 · accession 0001493152-23-030254 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2023-05-31 · accession 0001493152-24-034208 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2024-05-31 · accession 0001641172-25-026041 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2022-05-31 · accession 0001493152-23-030254 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2023-05-31 · accession 0001493152-24-034208 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2024-05-31 · accession 0001641172-25-026041 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2025-05-31 · accession 0001493152-26-040851 (CashAndCashEquivalentsAtCarryingValue)